Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485953 · ClinicalTrials.gov registry record · Phase 4
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
A Phase 4 study, sponsored by Susan L. Greenspan.
- Completed
- Registry status
- Phase 4
- Development phase
- 109
- Enrollment target
NCT00485953 is a Phase 4 study that has completed, run by Susan L. Greenspan. The registered enrollment target is 109 participants.
The verdict
NCT00485953, a Phase 4 study, has completed, sponsored by Susan L. Greenspan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 109 participants
- Enrollment target
Study Summary
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1) prevent bone loss at clinically relevant sites, such as the spine and hip and (2) decrease bone turnover.
Interventions
- DRUG risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00485953
The ClinicalTrials.gov registry entry for NCT00485953 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susan L. Greenspan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risedronate is the first listed.
NCT00485953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00485953 about?
NCT00485953 is a clinical study titled "Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy". Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1) prevent bone loss at clinical...
What is the current status of trial NCT00485953?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2007-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00485953?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00485953?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.